Traws Pharma Reports $7.1 Million Net Loss and No Revenue in Latest Quarter

Traws Pharma, Inc. reported significant financial challenges in its latest quarterly filing, revealing a net loss of $7.1 million for the three months ended March 31, 2026, compared to a net income of $21.5 million during the same period in 2025. The company did not generate any revenue in the latest quarter, a decrease from $57,000 in the prior year. Operating expenses rose to $6.9 million, up from $5.3 million, primarily driven by increased research and development costs, which surged by 96% to $4.9 million, reflecting ongoing clinical activities for its product candidates.

The company's balance sheet as of March 31, 2026, showed total assets of $8.2 million, down from $10.6 million at the end of 2025. Current liabilities increased to $13.2 million, up from $11.1 million, leading to a stockholders' deficit of $5.3 million, compared to a deficit of $629,000 at the end of the previous fiscal year. The increase in liabilities was attributed to higher accounts payable and accrued expenses, indicating a growing financial strain on the company.

Strategically, Traws Pharma has been active in its clinical development efforts, particularly following its merger with Trawsfynydd Therapeutics in April 2024. The company is focusing on four clinical programs, including tivoxavir marboxil for influenza and ratutrelvir for COVID-19. The company has also initiated a Phase 2 study for ratutrelvir and is preparing for a human challenge trial for tivoxavir marboxil. However, the company faces a clinical hold on its U.S. IND for tivoxavir marboxil due to concerns regarding its toxicology data, which it is currently addressing with the FDA.

As of the end of March 2026, Traws Pharma had cash and cash equivalents of $3.1 million, raising concerns about its ability to sustain operations for the next year without additional financing. The company has indicated that it will require substantial additional funding to support its ongoing clinical trials and operations. In April 2026, Traws Pharma completed a financing round that could provide up to $60 million, which includes upfront proceeds and milestone-based warrants. However, the company cautioned that it may not be able to secure sufficient capital on favorable terms, which could adversely affect its business and financial condition moving forward.